Cobro Ventures — Full Portfolio
7 tracked investments · listed companies and verified rows first
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalBain Capital Life SciencesNextech InvestRA Capital
AI Proteins designs engineered miniproteins for drug discovery and development in the biopharmaceutical industry.
AI & Machine LearningBiotechDeep TechAndover, US
Chris Bahl(Executive Officer, Director)inDominique Verhelle(Director)Bill McKee(Director)Julia Novina(Executive Officer)Marc A. Cohen(Executive Officer, Director)inGeoff Meyerson(Director)
Board seatTodd Kaloudis· per SEC Form D
Co-investorsMission BiocapitalTachyon Ventures
Windgap Medical designs autoinjector devices for delivering complex drugs and combination products, including systems for reconstituting lyophilized or powdered compounds, sequential delivery of two liquid therapies, high-viscosity medications, and large-volume injections.
BiotechHardwareMedical DevicesWatertown, US
Brent Buchine(Director)inMax Meehan(Executive Officer)inAaron Mann(Executive Officer, Director)inJason Durkin(Executive Officer)inJohn Cadigan(Executive Officer)inAnthony Watson(Executive Officer)in
Co-investorsBantam GroupBoston Harbor AngelsColle Capital PartnersLaunchpad Venture GroupTaiwania Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Microbial Machines, Inc.NextRNA TherapeuticsMana TherapeuticsRegenacy Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.